INDIANAPOLIS, May 22, 2021 /PRNewswire/ In a pre-specified analysis of the Phase 2 SERENITY study, Eli Lilly and Company s mirikizumab improved fatigue in patients with moderately to severely. | May 22, 2021
Mirikizumab Improves Fatigue in Patients with Crohn's Disease in Phase 2 Trial prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.<br />